- Home
- IBRX vs BYD Comparison
IBRX vs BYD Comparison
Compare IBRX & BYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | BYD |
|---|---|---|
| Founded | 2014 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.7B |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | IBRX | BYD |
|---|---|---|
| Price | $7.41 | $83.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 11 |
| Target Price | $12.57 | ★ $91.00 |
| AVG Volume (30 Days) | ★ 14.7M | 684.6K |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.81% |
| EPS Growth | 38.71 | ★ 264.46 |
| EPS | N/A | ★ 22.56 |
| Revenue | $113,288,000.00 | ★ $2,626,730,000.00 |
| Revenue This Year | $88.59 | $1.71 |
| Revenue Next Year | $131.15 | $2.74 |
| P/E Ratio | ★ N/A | $3.96 |
| Revenue Growth | ★ 668.31 | 9.41 |
| 52 Week Low | $1.83 | $67.67 |
| 52 Week High | $12.43 | $89.96 |
Technical Indicators
Market Signals| Indicator | IBRX | BYD |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 46.63 |
| Support Level | $2.22 | $79.52 |
| Resistance Level | $8.28 | $86.16 |
| Average True Range (ATR) | 0.56 | 2.26 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 39.03 | 39.22 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About BYD Boyd Gaming Corporation
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.